115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于 Cu-Cy Nps@ZIF-8@HA 的光动力疗法用于治疗皮肤鳞状细胞癌
Authors Li N, Wan X, Hou X, Zhang J, Zhang C, Sun Y, Wang F, Kong S, Yang C , Jiang G
Received 12 August 2025
Accepted for publication 9 December 2025
Published 8 January 2026 Volume 2026:21 560049
DOI https://doi.org/10.2147/IJN.S560049
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Eng San Thian
Na Li,1,* Xiao Wan,1,2,* Xiaoyang Hou,3 Jingxi Zhang,3 Congcong Zhang,3 Yao Sun,3 Fengdi Wang,3 Shujing Kong,3 Chunsheng Yang,4 Guan Jiang3
1The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, People’s Republic of China; 2Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 3Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, People’s Republic of China; 4Department of Dermatology, the Affiliated Huai’an Hospital of Xuzhou Medical University, The Second People’s Hospital of Huai’an, Huai’an, Jiangsu, 223002, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Guan Jiang, Email dr.guanjiang@xzhmu.edu.cn Chunsheng Yang, Email 8yung@sina.com
Purpose: The complex tumor microenvironment poses an important challenge for the effective treatment of tumors, so it is important to develop efficient multimodal nanomaterials for tumor therapy. This study introduces a novel nanomaterial, Cu-Cy Nps@ZIF-8@HA (CNZH), based on zeolitic imidazolate framework-8 (ZIF-8) backbone. CNZH offers the combined merits of facile synthesis, environmental benignity, and effective therapeutic performance against cutaneous squamous cell carcinoma(cSCC).
Patients and Methods: The photosensitizer Cu-cy Nps (Cu-Cy Nanoparticles) was initially synthesized and subsequently encapsulated within a zeolitic imidazolate framework-8 framework to construct Cu-cy Nps@ZIF-8 (CNZ), which was further surface-modified with hyaluronic acid(HA) to yield the final nanocomposite CNZH. In vitro evaluations demonstrated excellent biocompatibility, as evidenced by hemolysis assays and CCK-8 cytotoxicity tests. Transmission electron microscopy (TEM) confirmed efficient cellular uptake by A-431 cells, while Western blot analysis validated its tumor-targeting specificity. Functional characterization revealed CNZH’s remarkable capacity for reactive oxygen species(ROS) generation, GSH depletion, and singlet oxygen (1O2) production. For in vivo assessment, an A-431 xenograft mouse model was established, with subsequent tumor tissue analyses including TUNEL apoptosis assay, ROS staining, and immunohistochemical examination, collectively demonstrating the nanocomposite’s significant therapeutic efficacy and precise tumor-targeting capability.
Results: This study successfully designed and fabricated a novel ZIF-8-based nanomaterial, CNZH, which exhibits POD, CAT, and GSH-Px enzymatic activities along with the capability to generate 1O2. In vitro, the apoptosis rate of A-431 cells treated with LCNZH (CNZH+UV) was 77.1% (predominantly early apoptosis),the survival rate of A-431 cells treated with 200 μg/mL CNZH for 24h was 32%, which was significantly lower than that of the CNZ group (65%, P< 0.05). In vivo, the tumor volume of the LCNZH group was significantly smaller than that of the PBS and CNZ groups after 12 days of treatment. PBS control, no-light groups Both in vitro and in vivo experimental results demonstrated that CNZH can effectively target tumor cells, synergistically exert outstanding anti-cancer effects through combined CDT/PDT therapy, while maintaining excellent biosafety.
Conclusion: CNZH is expected to be a highly efficient nanomaterial for the synergistic treatment of cutaneous squamous cell carcinoma, thereby opening up a new avenue for the application of nanomaterials in the treatment of this malignancy.
Keywords: nanomaterials, synergistic therapy, chemodynamic therapy, CDT, photodynamic therapy, PDT, cutaneous squamous cell carcinoma, cSCC
1The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, People’s Republic of China; 2Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 3Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, People’s Republic of China; 4Department of Dermatology, the Affiliated Huai’an Hospital of Xuzhou Medical University, The Second People’s Hospital of Huai’an, Huai’an, Jiangsu, 223002, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Guan Jiang, Email dr.guanjiang@xzhmu.edu.cn Chunsheng Yang, Email 8yung@sina.com
Purpose: The complex tumor microenvironment poses an important challenge for the effective treatment of tumors, so it is important to develop efficient multimodal nanomaterials for tumor therapy. This study introduces a novel nanomaterial, Cu-Cy Nps@ZIF-8@HA (CNZH), based on zeolitic imidazolate framework-8 (ZIF-8) backbone. CNZH offers the combined merits of facile synthesis, environmental benignity, and effective therapeutic performance against cutaneous squamous cell carcinoma(cSCC).
Patients and Methods: The photosensitizer Cu-cy Nps (Cu-Cy Nanoparticles) was initially synthesized and subsequently encapsulated within a zeolitic imidazolate framework-8 framework to construct Cu-cy Nps@ZIF-8 (CNZ), which was further surface-modified with hyaluronic acid(HA) to yield the final nanocomposite CNZH. In vitro evaluations demonstrated excellent biocompatibility, as evidenced by hemolysis assays and CCK-8 cytotoxicity tests. Transmission electron microscopy (TEM) confirmed efficient cellular uptake by A-431 cells, while Western blot analysis validated its tumor-targeting specificity. Functional characterization revealed CNZH’s remarkable capacity for reactive oxygen species(ROS) generation, GSH depletion, and singlet oxygen (1O2) production. For in vivo assessment, an A-431 xenograft mouse model was established, with subsequent tumor tissue analyses including TUNEL apoptosis assay, ROS staining, and immunohistochemical examination, collectively demonstrating the nanocomposite’s significant therapeutic efficacy and precise tumor-targeting capability.
Results: This study successfully designed and fabricated a novel ZIF-8-based nanomaterial, CNZH, which exhibits POD, CAT, and GSH-Px enzymatic activities along with the capability to generate 1O2. In vitro, the apoptosis rate of A-431 cells treated with LCNZH (CNZH+UV) was 77.1% (predominantly early apoptosis),the survival rate of A-431 cells treated with 200 μg/mL CNZH for 24h was 32%, which was significantly lower than that of the CNZ group (65%, P< 0.05). In vivo, the tumor volume of the LCNZH group was significantly smaller than that of the PBS and CNZ groups after 12 days of treatment. PBS control, no-light groups Both in vitro and in vivo experimental results demonstrated that CNZH can effectively target tumor cells, synergistically exert outstanding anti-cancer effects through combined CDT/PDT therapy, while maintaining excellent biosafety.
Conclusion: CNZH is expected to be a highly efficient nanomaterial for the synergistic treatment of cutaneous squamous cell carcinoma, thereby opening up a new avenue for the application of nanomaterials in the treatment of this malignancy.
Keywords: nanomaterials, synergistic therapy, chemodynamic therapy, CDT, photodynamic therapy, PDT, cutaneous squamous cell carcinoma, cSCC